JP2023500391A5 - - Google Patents
Info
- Publication number
- JP2023500391A5 JP2023500391A5 JP2022526822A JP2022526822A JP2023500391A5 JP 2023500391 A5 JP2023500391 A5 JP 2023500391A5 JP 2022526822 A JP2022526822 A JP 2022526822A JP 2022526822 A JP2022526822 A JP 2022526822A JP 2023500391 A5 JP2023500391 A5 JP 2023500391A5
- Authority
- JP
- Japan
- Prior art keywords
- albumin
- mutation
- cancer
- composition
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962933820P | 2019-11-11 | 2019-11-11 | |
| US62/933,820 | 2019-11-11 | ||
| US202062991469P | 2020-03-18 | 2020-03-18 | |
| US62/991,469 | 2020-03-18 | ||
| PCT/US2020/060070 WO2021096997A1 (en) | 2019-11-11 | 2020-11-11 | Biomarkers for nanoparticle compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023500391A JP2023500391A (ja) | 2023-01-05 |
| JP2023500391A5 true JP2023500391A5 (enExample) | 2023-11-20 |
Family
ID=75912683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526822A Pending JP2023500391A (ja) | 2019-11-11 | 2020-11-11 | ナノ粒子組成物のためのバイオマーカー |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20230000844A1 (enExample) |
| EP (1) | EP4058000A4 (enExample) |
| JP (1) | JP2023500391A (enExample) |
| KR (1) | KR20220113699A (enExample) |
| CN (1) | CN114945358A (enExample) |
| AU (1) | AU2020382817A1 (enExample) |
| BR (1) | BR112022009018A2 (enExample) |
| CA (1) | CA3161105A1 (enExample) |
| IL (1) | IL292859A (enExample) |
| MX (1) | MX2022005715A (enExample) |
| TW (1) | TW202123935A (enExample) |
| WO (1) | WO2021096997A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| SMT202100642T1 (it) | 2015-06-29 | 2022-03-21 | Abraxis Bioscience Llc | Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi |
| AU2019239953B2 (en) | 2018-03-20 | 2025-01-02 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| IL292439B2 (en) | 2019-10-28 | 2026-05-01 | Abraxis Bioscience Llc | Pharmaceutical preparations of albumin and rapamycin |
| US20260137665A1 (en) * | 2022-10-11 | 2026-05-21 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| WO2024228964A1 (en) * | 2023-04-30 | 2024-11-07 | Aadi Bioscience, Inc. | Treatments comprising an mtor inhibitor nanoparticle composition |
| WO2025129108A1 (en) | 2023-12-14 | 2025-06-19 | Aadi Bioscience, Inc. | Methods of treating a cancer in an individual |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3417859A1 (en) * | 2007-03-07 | 2018-12-26 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US20140186447A1 (en) * | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| JP6309610B2 (ja) * | 2013-03-14 | 2018-04-11 | アブラクシス バイオサイエンス， エルエルシー | 膀胱がんを処置する方法 |
| WO2015170248A1 (en) * | 2014-05-05 | 2015-11-12 | Cellworks Research India Pvt. Ltd. | Combination of nelfinavir, metformin and rosuvastatin for treating cancer caused by aberrations in pten/tp53 |
| US20180177771A1 (en) * | 2015-06-29 | 2018-06-28 | Abraxis Bioscience, Llc | Biomarkers for nanoparticle compositions |
| SMT202100642T1 (it) * | 2015-06-29 | 2022-03-21 | Abraxis Bioscience Llc | Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi |
| JP2018521058A (ja) * | 2015-06-29 | 2018-08-02 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して固形腫瘍を処置する方法 |
| SG11202005613SA (en) * | 2017-12-19 | 2020-07-29 | Abraxis Bioscience Llc | Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy |
| MX2021011230A (es) * | 2019-03-19 | 2022-03-11 | Abraxis Bioscience Llc | Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades. |
-
2020
- 2020-11-11 CN CN202080092690.1A patent/CN114945358A/zh active Pending
- 2020-11-11 EP EP20887933.8A patent/EP4058000A4/en active Pending
- 2020-11-11 KR KR1020227019284A patent/KR20220113699A/ko not_active Ceased
- 2020-11-11 BR BR112022009018A patent/BR112022009018A2/pt unknown
- 2020-11-11 TW TW109139395A patent/TW202123935A/zh unknown
- 2020-11-11 AU AU2020382817A patent/AU2020382817A1/en not_active Abandoned
- 2020-11-11 CA CA3161105A patent/CA3161105A1/en active Pending
- 2020-11-11 IL IL292859A patent/IL292859A/en unknown
- 2020-11-11 WO PCT/US2020/060070 patent/WO2021096997A1/en not_active Ceased
- 2020-11-11 MX MX2022005715A patent/MX2022005715A/es unknown
- 2020-11-11 US US17/775,562 patent/US20230000844A1/en not_active Abandoned
- 2020-11-11 JP JP2022526822A patent/JP2023500391A/ja active Pending
- 2020-12-02 US US17/110,133 patent/US20210137848A1/en not_active Abandoned
-
2022
- 2022-12-19 US US18/084,411 patent/US20230293449A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rahal et al. | Genomics of adult and pediatric solid tumors | |
| JP2013523744A5 (enExample) | ||
| Wu et al. | Recent advances in ferrocene-based nanomedicines for enhanced chemodynamic therapy | |
| Shang et al. | Insights into CSF-1/CSF-1R signaling: the role of macrophage in radiotherapy | |
| Jones et al. | Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer | |
| Jachowski et al. | Modern therapies of nonsmall cell lung cancer | |
| Shen et al. | Ultrasound‐triggered cascade delivery via poly‐oxaliplatin nanoparticles for immunotherapy | |
| JP6410795B2 (ja) | カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物 | |
| JP2015503613A5 (enExample) | ||
| Chuang et al. | Targeted therapies for the treatment of glioblastoma in adults | |
| KR20220113699A (ko) | 나노입자 조성물에 대한 바이오마커 | |
| CN111565799A (zh) | 治疗神经内分泌肿瘤的方法 | |
| Sukrithan et al. | Kinase inhibitors in thyroid cancers | |
| Han et al. | Supramolecular engineering of molecular inhibitors in an adaptive cytotoxic nanoparticle for synergistic cancer therapy | |
| WO2021018310A1 (zh) | 用于治疗非小细胞肺癌的氨基吡啶衍生物 | |
| Częścik et al. | Evolution or revolution in colorectal cancer treatment: present and future of new therapeutic options. A narrative review | |
| Chen et al. | New strategies to enhance the efficacy of PD-1/PD-L1 inhibitors in treating microsatellite stable colorectal cancer | |
| Gao et al. | Theranostic nanoplatform based on polydopamine-coated magnetic mesoporous silicon for precise cancer triplex nanotherapy and multimodal imaging | |
| JP2024063000A (ja) | 新規なクレノラニブの使用 | |
| JP2021501203A5 (enExample) | ||
| Pindiprolu et al. | Nanocarrier-mediated modulation of cGAS-STING signaling pathway to disrupt tumor microenvironment | |
| Wang et al. | Perspectives of metal-organic framework nanosystem to overcome tumor drug resistance | |
| Seol et al. | A pilot prospective study of refractory solid tumor patients for NGS-based targeted anticancer therapy | |
| Li et al. | Drug-loaded Biomimetic carriers for Non-hodgkin’s lymphoma therapy: advances and perspective | |
| Abudurexiti et al. | The mechanisms of imatinib resistance in gastrointestinal stromal tumours: theoretical basis and therapeutic aspect |